SAN DIEGO, Sept. 9 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.
(Nasdaq: ANDS) announced today that dosing has begun in a Phase II trial of
ANA598 in patients chronically infected with hepatitis C virus (HCV). The
study will evaluate ANA598 over 12 weeks, taken in combination with pegylated
interferon-alpha and ribavirin, in treatment naive HCV patients. ANA598 is an
investigational, oral, non-nucleoside polymerase inhibitor.
